Harmonic Discovery
Developing multi-target drugs using a computational-experimental platform.
Developing multi-target drugs using a computational-experimental platform.
Harmonic Discovery, founded with the mission to revolutionize drug discovery, focuses on developing multi-targeted therapeutics to treat complex diseases such as cancer and autoimmunity. The company leverages a computational-experimental platform to design drugs that can simultaneously target multiple dysregulated proteins across various biological pathways, addressing the limitations of the traditional one drug-one protein approach. Their innovative solutions aim to reduce side effects and enhance therapeutic efficacy by embracing the complexity of disease mechanisms.
Notable figures associated with Harmonic Discovery include experts in computational biology and pharmacology, though specific names are not provided. The company has garnered attention from key investors in the biotech sector, supporting its groundbreaking work. Harmonic Discovery's achievements include the development of a robust platform that integrates computational and experimental methods, positioning it as a pioneer in precision pharmacology. The overall impact of their work promises significant advancements in treating multifaceted diseases, potentially transforming therapeutic strategies and patient outcomes.
Companies similar to Harmonic Discovery include Unravel Biosciences, Ensem Therapeutics, Vilya and Relay Therapeutics.
Harmonic Discovery was founded in 2021.
Harmonic Discovery's headquarters is located in New York City, NY, US.
Harmonic Discovery's most recent funding round was for $8M (USD) in September 2022.
As of Sep 8, 2022, Harmonic Discovery has disclosed funding of $8.1M (USD). Undisclosed round amounts are excluded.
Harmonic Discovery has 12 employees as of Feb 5, 2024.
Relay Therapeutics
relaytx.com
